新辅助帕米帕利联合阿比特龙及ADT治疗高危/极高危局限前列腺癌的II期研究
这项开放标签单臂II期研究评估了新辅助帕米帕利联合阿比特龙及雄激素剥夺治疗(ADT)在高危/极高危局限前列腺癌(HRPCa/VHRPCa)患者中的疗效、安全性和生活质量影响。
要点
- 新辅助帕米帕利+阿比特龙+ADT方案在HRPCa/VHRPCa中显示28%的pCR/MRD率和62%的手术降期率。
- 2年bPFS为76%,未发生3-4级治疗相关不良事件。
- FACT-P评分在62%患者中改善,术后41%维持改善。
核心结论
- 新辅助帕米帕利联合阿比特龙及ADT在HRPCa/VHRPCa中显示出疗效、安全性和潜在生活质量获益。
研究设计与样本
- 患者接受帕米帕利联合阿比特龙及ADT治疗4个月后行根治性前列腺切除术,主要终点为pCR或MRD(≤5 mm残留肿瘤)。
主要发现
- 29例完成治疗并接受手术,中位年龄65岁,9例盆腔淋巴结增大,7例检测到同源重组修复(HRR)突变。
- 8例(28%)达到pCR或MRD(pCR 3例[10%],MRD 5例[17%]),18例(62%)实现手术降期,无进展事件。
- HRR突变与无HRR突变患者间pCR或MRD率无显著差异,2年bPFS为76%。
- FACT-P评分在18例(62%)治疗期间改善,22例中9例(41%)术后维持改善;12个月时平均EPIC-26尿失禁评分为83.2±12.5。
- 未发生3-4级治疗相关不良事件;常见1-2级事件为贫血(45%)、AST/ALT升高(34%)和高甘油三酯血症(45%)。
关键数值与推荐
- pCR或MRD率为28%(pCR 10%,MRD 17%),手术降期率62%,2年bPFS 76%。
- 常见1-2级不良事件:贫血45%,AST/ALT升高34%,高甘油三酯血症45%;无3-4级治疗相关不良事件。
临床怎么用
- 该联合方案可作为高危/极高危局限前列腺癌新辅助治疗的一种潜在选择,需关注贫血、肝酶升高和高甘油三酯血症等1-2级不良事件。
- HRR突变状态可能不影响pCR/MRD率,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen receptor signaling inhibition (ARPI) increases genomic instability of double-stranded DNA breaks, and co-inhibition of androgen receptor (AR) and poly(ADP-ribose) polymerase (PARP) induces synthetic lethality in multiple preclinical models. This phase II study evaluated the efficacy, safety, and quality-of-life (QoL) impact of neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy (ADT) in patients with high-risk or very high-risk localized prostate cancer (HRPCa/VHRPCa). METHODS: In this single-arm trial, patients with HRPCa/VHRPCa, defined as Gleason score ≥8, and/or cT3-4N0-1, and/or PSA ≥ 20 ng/mL, received pamiparib plus abiraterone and ADT for 4 months before radical prostatectomy (RP). The primary endpoint was pathological complete response (pCR; no residual tumor) or minimal residual disease (MRD; ≤5 mm residual tumor). Secondary endpoints included PSA response, surgical downstaging, 2-year biochemical progression-free survival (bPFS), QoL metrics, and safety. RESULTS: Thirty patients were enrolled; 29 completed therapy and underwent RP. Median age was 65 years, and 9 patients had enlarged pelvic lymph nodes. Homologous recombination repair (HRR) mutations were detected in 7 patients. Overall, 8 patients (28%) achieved pCR or MRD (pCR in 3 [10%], MRD in 5 [17%]), and 18 patients (62%) had surgical downstaging, with no progression events. No significant difference in pCR or MRD rates was observed between patients with HRR mutations and those without HRR mutations. Two-year bPFS was 76%. FACT-P scores improved in 18 patients (62%) during therapy, with 9 of 22 (41%) maintaining improvement postoperatively. At 12 months, mean EPIC-26 urinary incontinence score was 83.2 ± 12.5. No grade 3-4 treatment-related adverse events occurred; common grade 1-2 events were anemia (45%), elevated AST/ALT (34%), and hypertriglyceridemia (45%). CONCLUSIONS: Neoadjuvant pamiparib plus abiraterone and ADT demonstrated efficacy, safety, and potential QoL benefits in HRPCa/VHRPCa.
引用
- Gong T, Liang S, Wu Z, et al. Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. Prostate Cancer Prostatic Dis. 2025. PMID: 41454188. doi:10.1038/s41391-025-01068-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。